CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of CEL-SCI (NYSE:CVM) in a research note issued to investors on Saturday. The brokerage issued a sell rating on the stock.

CEL-SCI Stock Down 3.2 %

Shares of CVM opened at $0.38 on Friday. The company has a market capitalization of $27.92 million, a PE ratio of -0.74 and a beta of 0.65. The business’s 50 day moving average is $0.52 and its 200 day moving average is $0.85. The company has a current ratio of 1.31, a quick ratio of 1.09 and a debt-to-equity ratio of 0.62. CEL-SCI has a 12-month low of $0.36 and a 12-month high of $3.08.

Institutional Trading of CEL-SCI

Hedge funds and other institutional investors have recently bought and sold shares of the business. Calton & Associates Inc. acquired a new stake in shares of CEL-SCI during the third quarter valued at about $50,000. Plotkin Financial Advisors LLC purchased a new position in CEL-SCI during the 3rd quarter worth approximately $98,000. Renaissance Technologies LLC grew its position in CEL-SCI by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 173,800 shares of the company’s stock worth $202,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of CEL-SCI by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 612,861 shares of the company’s stock valued at $650,000 after buying an additional 53,879 shares during the period. 12.08% of the stock is currently owned by institutional investors and hedge funds.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.